Exelixis (EXEL) Given Hold Rating at Oppenheimer

Oppenheimer reiterated their hold rating on shares of Exelixis (NASDAQ:EXEL) in a report released on Thursday.

Several other research firms also recently commented on EXEL. SunTrust Banks reissued a buy rating and issued a $38.00 price objective on shares of Exelixis in a research note on Thursday, December 21st. Zacks Investment Research raised Exelixis from a hold rating to a buy rating and set a $29.00 price objective for the company in a research note on Tuesday, October 10th. Needham & Company LLC increased their price objective on Exelixis from $30.00 to $33.00 and gave the company a buy rating in a research note on Tuesday, October 17th. Piper Jaffray Companies reissued a buy rating and issued a $29.00 price objective on shares of Exelixis in a research note on Sunday, September 10th. Finally, Royal Bank of Canada increased their price objective on Exelixis from $33.00 to $39.00 and gave the company an outperform rating in a research note on Tuesday, October 17th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $32.13.

Exelixis (NASDAQ:EXEL) traded down $0.27 during midday trading on Thursday, reaching $31.62. The company had a trading volume of 2,177,609 shares, compared to its average volume of 2,900,667. Exelixis has a 1 year low of $14.90 and a 1 year high of $32.50. The firm has a market cap of $9,350.00, a P/E ratio of 64.53, a P/E/G ratio of 0.95 and a beta of 1.88.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The firm had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. During the same period in the prior year, the company earned ($0.04) EPS. The firm’s revenue was up 145.2% compared to the same quarter last year. equities analysts predict that Exelixis will post 0.49 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the business. FMR LLC grew its holdings in Exelixis by 2.0% in the 2nd quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock valued at $1,077,530,000 after buying an additional 857,452 shares in the last quarter. Vanguard Group Inc. grew its holdings in Exelixis by 7.2% in the 2nd quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock valued at $626,635,000 after buying an additional 1,706,893 shares in the last quarter. Matrix Capital Management Company LP grew its holdings in Exelixis by 8.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after buying an additional 1,225,000 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Exelixis by 13.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock valued at $173,869,000 after buying an additional 818,782 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in Exelixis by 6.5% in the 3rd quarter. Jennison Associates LLC now owns 3,061,003 shares of the biotechnology company’s stock valued at $74,168,000 after buying an additional 187,654 shares in the last quarter. Institutional investors own 81.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/05/exelixis-exel-given-hold-rating-at-oppenheimer-2.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

What are top analysts saying about Exelixis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exelixis and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit